Effect of extended MMX mesalamine therapy for acute, midl-to-moderate Ulcerative Colitis

Inflammatory Bowel Diseases

Volumn 15, Issue 1, 2009, Pages 1-8

  Kamm, Michael A ^a,b   Lichtenstein, Gary R ^c   Sandborn, William J ^d   Schreiber, Stefan ^e   Lees, Kirstin ^f   Barrett, Karen ^g   Joseph, Raymond ^f  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF KIEL   (Germany)

^f SHIRE   (United States)

^g Shire Pharmaceuticals   (United Kingdom)

Author keywords

5 aminosalicylic acid; Inflammatory bowel disease; Mesalamine; Multi matrix system; Ulcerative colitis

Indexed keywords

MESALAZINE; PLACEBO; NONSTEROID ANTIINFLAMMATORY AGENT;

ACTIVITY INDEX SCORE; ADULT; ARTICLE; CLINICAL TRIAL; DEFECATION HABIT; DELAYED RELEASE FORMULATION; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG COATING; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; HUMAN; INFECTION; INFESTATION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NAUSEA; NEUROLOGIC DISEASE; PANCREATITIS; PATIENT COMPLIANCE; PHYSICIAN GLOBAL ASSESSMENT SCORE; PRIORITY JOURNAL; RECTUM HEMORRHAGE; REMISSION; SCORING SYSTEM; SIGMOIDOSCOPY; TABLET; TREATMENT DURATION; TREATMENT FAILURE; ULCERATIVE COLITIS; VOMITING; ACUTE DISEASE; DOSE RESPONSE; INTERNATIONAL COOPERATION; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERNATIONAL AGENCIES; MALE; MAXIMUM TOLERATED DOSE; MESALAMINE; PROGNOSIS; REMISSION INDUCTION; SIGMOIDOSCOPY; TREATMENT OUTCOME;

EID: 61949292991     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20580     Document Type: Article

References (27)

1. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53:V1-16.
2. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371-1385.
3. Loftus EV Jr. A practical perspective on ulcerative colitis: patients' needs from aminosalicylate therapies. Inflamm Bowel Dis. 2006;12: 1107-1113.
4. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;CD000544.
5. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006; CD000543.
6. Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96:2929-2933.
7. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:577-585.
8. Han SW, McColl E, Barton JR, et al. Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations. Inflamm Bowel Dis. 2005;11:24-34.
9. Janke KH, Klump B, Gregor M, et al. Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:272-286.
10. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003; 114:39-43.
11. van Hees PA, van Tongeren JH. Compliance to therapy in patients on a maintenance dose of sulfasalazine. J Clin Gastroenterol. 1982;4:333-336.
12. Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis. 2005;11:421-427.
13. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007;5:95-102.
14. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily high concentration MMX mesalamine in active ulcerative colitis: placebo and active comparator-controlled study. Gastroenterology. 2007;132:66-75.
15. Sandborn WJ, Kamm MA, Lichtenstein GR, et al. Multi Matrix System (MMX®) mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Alim Pharmacol Ther. 2007;26:205-215.
16. Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol. 2001;33:289-294.
17. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940-987.
18. Green JR, Lobo AJ, Holdsworth CD, et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology. 1998;114: 15-22.
19. Green JR, Mansfield JC, Gibson JA, et al. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther. 2002;16:61-68.
20. Hanauer SB, Barish C, Pambianco D, et al. A multi-center, double-blind, placebo-controlled, dose-ranging trial of olsalazine for mild-moderately active ulcerative colitis. Gastroenterology. 1996;110:A921.
21. Mahmood A, Melley L, Fitzgerald AJ, et al. Trial of trefoil factor 3 enemas, in combination with oral 5-aminosalicylic acid, for the treatment of mild-to-moderate left-sided ulcerative colitis. Aliment Pharmacol Ther. 2005;21:1357-1364.
22. Sinha A, Nightingale J, West KP, et al. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med. 2003;349:350-357.
23. Biddle WL, Miner PB Jr. Long-term use of mesalamine enemas to induce remission in ulcerative colitis. Gastroenterology. 1990; 99:113-118.
24. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92:1894-1898.
25. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763-786.
26. Adachi E, Okazaki K, Matsushima Y, et al. Acute pancreatitis secondary to 5-aminosalicylic acid therapy in a patient with ulcerative colitis. Int J Pancreatol. 1999;25:217-221.
27. Decocq G, Gras-Champel V, Vrolant-Mille C, et al. [Acute pancreatitis induced by drugs derived from 5-aminosalicylic acid: case report and review of the literature.] Therapie. 1999;54:41-48.